Results of placing and subscription

ANGLE plc (AIM: AGL), a world-leading liquid biopsy company is pleased to announce that, following the announcement made earlier today (the "Launch Announcement") regarding the launch of a proposed Placing and Subscription, it has successfully raised aggregate gross proceeds of £8.775 million.

A total of 33,499,998 Placing Shares have been placed by Joh. Berenberg, Gossler & Co. KG ("Berenberg") and Beech Hill Securities, Inc. ("Beech Hill") and a total of 25,000,002 Subscription Shares have been subscribed for in the Subscription, in each case at an Issue Price of 15 pence per share.

The Issue Price represents a discount of approximately 16.7% per cent. to the closing price of 18 pence on 4 June 2024, being the last business day prior to the Launch Announcement.

Application has been made for the Placing Shares and Subscription Shares to be admitted to trading on AIM. Admission and settlement of the Placing Shares and Subscription Shares is expected to take place at 8.00 a.m. on 11 June 2024 (or such later time and/or date as may be agreed between the Company and Berenberg, being no later than 8.00 a.m. on 25 June 2024). The Placing is conditional upon, among other things, First Admission becoming effective and the Placing and Open Offer Agreement becoming unconditional in respect of the Placing and not being terminated in accordance with its terms prior to First Admission. The net proceeds of the Placing and Subscription are expected to be a minimum of c.£8.1 million.

The Placing Shares and Subscription Shares, when issued, will be fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company, including, without limitation, the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Open Offer

As announced earlier today, ANGLE plc also intends to raise up to approximately £2.06 million through the issue of up to 13,714,641 New Ordinary Shares pursuant to an Open Offer, to allow shareholders, including those who are not participating in the Placing and Subscription to subscribe for New Ordinary Shares at the Issue Price. The Company intends to publish and send a Circular to shareholders in connection with the Open Offer on 6 June 2024. The Circular will also be available on the Company's website: https://angleplc.com/ (subject to certain access restrictions).

Total voting rights

Following First Admission and before the issuance of any New Ordinary Shares taken up pursuant to the Open Offer, the Company will have a total of 319,080,547 ordinary shares in issue. With effect from First Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

ANGLE Chief Executive, Andrew Newland, commented:

"We are grateful for the strong support from existing shareholders and new investors. This fundraise, together with our existing cash balance, puts us in a strong position to capitalise on our building commercial momentum. There is a growing move towards personalised cancer care and we believe ANGLE's FDA-cleared Parsortix system provides the 'best sample' for analysis of cancer status. We have been very pleased with the recent contracts with large pharma and believe these represent the start of a growth phase for the Company."

Unless otherwise stated, capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the Launch Announcement published by the Company on 5 June 2024.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit https://angleplc.com/.

UK Product Governance Requirements

Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that such Placing Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all permitted distribution channels (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the UK Product Governance Requirements) should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.